Etravirine for the treatment of HIV infection

References

• Hammer SM, Saag MS, Schechter M et al. Treatment for adult HIV infection: 2006 recomendations of the International AIDS Society-USA panel. JAMA296, 827–843 (2006).
   PubMed Web of Science ®Google Scholar
• Andries K, Azijn H, Thielemans T et al. TMC125, a novel next-generation nonnucleoside reverse transcriptase inhibitor active against nonnucleoside reverse transcriptase inhibitor-resistant human immunodeficiency virus type 1. Antimicrob. Agents Chemother.48(12), 4680–4686 (2004).
   PubMed Web of Science ®Google Scholar
• Ross L, Lim ML, Liao Q et al. Prevalence of antiretroviral drug resistance and resistance-associated mutations in antiretroviral therapy-naive HIV-infected individuals from 40 United States cities. HIV Clin. Trials8(1), 1–8 (2007).
   PubMed Web of Science ®Google Scholar
• SPREAD programme. Transmission of drug-resistant HIV-1 in Europe remains limited to single classes. AIDS22(5), 625–635 (2008).
   PubMed Web of Science ®Google Scholar
• Wensing MJ, van de Vijver DA, Angarano G et al. Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: implications for clinical management. J. Infect. Dis.192, 958–966 (2005).
   PubMed Web of Science ®Google Scholar
• Das K, Clark AD Jr, Lewi PJ et al. Roles of conformational and positional adaptability in structure-based design of TMC125-R165335 [etravirine] and related non-nucleoside reverse transcriptase inhibitors that are highly potent and effective against wild-type and drug-resistant HIV-1 variants. J. Med. Chem.47(10), 2550–2560 (2004).
   PubMed Web of Science ®Google Scholar
• De Bethune MP, Hertogs K, Azijn H et al. R165335-TMC125, a third generation non nucleoside reverse transcriptase inhibitor [NNRTI], inhibits 98% of more than 2000 recombinant HIV clinical isolates at 100 nM. Presented at: 40th Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto, Canada, 17–20 September, 2000 (Abstract 1841).
   Google Scholar
• Vingerhoets J, Azijn H, Fransen E et al. TMC125 displays a high genetic barrier to the development of resistance: evidence from in vitro selection experiments. J. Virol.79(20), 12773–12782 (2005).
   PubMed Web of Science ®Google Scholar
• Vingerhoets J, Buelens A, Peeters M et al. Impact of baseline NNRTI mutations on the virologic response to TMC125 in the Phase III clinical trials DUET-1 and DUET-2. Presented at: 16th International HIV Drug Resistance Workshop, Barbados, 12–16 June, 2007 (Abstract 32).
   Google Scholar
• Libre J, Santos JR, Puig T et al. Prevalence of mutations with impact on virological response to etravirine in routine clinical samples. Presented at: 15th Conference on Retroviruses and Opportunistic Infections, MA, USA, 3–6 February, 2008 (Abstract 868).
   Google Scholar
• Kakuda T, Wade J, Snoeck E et al. Pharmacokinetics and pharmacodynamics of the NNRTI etravirine (ETR; TMC125) in treatment-experienced HIV-1-infected patients: pooled 24-week results of DUET-1 and DUET-2. Presented at: 15th Conference on Retroviruses and Opportunistic Infections, MA, USA, 3–6 February, 2008 (Abstract 762).
   Google Scholar
• Gruzdev B, Rakhmanova A, Doubovskaya E et al. A randomized, double-blind, placebo-controlled trial of TMC125 as 7-day monotherapy in antiretroviral naive, HIV-1 infected subjects. AIDS17(17), 2487–2494 (2003).
   PubMed Web of Science ®Google Scholar
• Scholler-Gyure M, Leemans R, Beets G et al. Effect of food on the oral bioavailability of the Phase III formulation of TMC125. Presented at: 7th International Workshop on Clinical Pharmacology of HIV Therapy. Lisbon, Portugal, 20–22 April, 2006 (Abstract 80).
   Google Scholar
• Kakuda T, Konlgs C, Felterna-Sperling C et al. Pharmacokinetics of the next-generation etravirine (ETR; TMC125) in HIV-infected children between 6 and 17 years, inclusive. Presented at: 15th Conference on Retroviruses and Opportunistic Infections, MA, USA, 3–6 February, 2008 (Abstract 578).
   Google Scholar
• Scholler-Gyure M, Kakuda TN, Sekar V et al. Pharmacokinetics of darunavir/ritonavir and TMC125 alone and coadministered in HIV-negative volunteers. Antivir. Ther.12(5), 789–796 (2007).
   PubMed Web of Science ®Google Scholar
• Boffito M, Winston A, Jackson A et al. Pharmacokinetics and antiretroviral response to darunavir/ritonavir and etravirine combination in patients with high-level viral resistance. AIDS21(11), 1449–1455 (2007).
   PubMed Web of Science ®Google Scholar
• Baede P, Piscitelli S, Graham N et al. Drug interactions with TMC125, a potent next generation NNRTI. Presented at: 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, September 27, 2002 (Abstract 27).
   Google Scholar
• Scholler-Gyure M, Kraft M, Hoetelmans R et al. Significant decrease in TMC125 exposures when co-administered with tipranavir boosted with ritonavir in healthy subjects. Presented at: 13th Conference on Retroviruses and Opportunistic Infections, CO, USA, 5–8 February, 2006 (Abstract 583).
   Google Scholar
• Scholler-Gyure M, van den Brink W, Kakuda T et al. Pharmacokinetic and pharmacodynamic study of the concomitant administration of methadone and TMC125 in HIV-negative volunteers. J. Clin. Pharmacol.48, 322–329 (2008).
   PubMed Web of Science ®Google Scholar
• Sankatsing SU, Weverling GJ, Peeters M et al. TMC125 exerts similar initial antiviral potency as a five-drug, triple class antiretroviral regimen. AIDS17(18), 2623–2627 (2003).
   PubMed Web of Science ®Google Scholar
• Gazzard BG, Pozniak AL, Rosenbaum W et al. An open-label assessment of TMC 125 – a new, next-generation NNRTI, for 7 days in HIV-1 infected individuals with NNRTI resistance. AIDS17(18), F49–F54 (2003).
   PubMed Web of Science ®Google Scholar
• Nadler JP, Berger DS, Blick G et al.; TMC125-C223 Writing Group. Efficacy and safety of etravirine (TMC125) in patients with highly resistant HIV-1: primary 24-week analysis. AIDS21(6), F1–F10 (2007).
   Google Scholar
• Woodfall B, Vingerhoets J, Peeters M et al. Impact of NNRTI and NRTI resistance on the response to the regimen of TMC125 plus two NRTIs in study TMC125-C227. Presented at: 8th International Congress on Drug Therapy in HIV Infection. Glasgow, Scotland (2006) (Abstract PL5.6).
   Google Scholar
• Madruga JV, Cahn P, Grinsztejn B et al. Efficacy and safety of TMC125 [etravirine] in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet370(9581), 29–38 (2007).
   PubMed Web of Science ®Google Scholar
• Lazzarin A, Campbell T, Clotet B et al. Efficacy and safety of TMC125 [etravirine] in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet370(9581), 39–48 (2007).
   PubMed Web of Science ®Google Scholar
• Haubric R, Cahn P, Grinsztejn B et al. DUET-1: week 48 results of a Phase III randomised double-blind trial to evaluate the efficacy and safety of etravirine (ETR; TMC125) versus placebo in 591 treatment-experienced HIV-1-infected patients. 15th Conference on Retroviruses and Opportunistic Infections, MA, USA, 3–6 February, 2008 (Abstract 790).
   Google Scholar
• Campbell T, A Mills, P Morlat et al. TMC125 safety and tolerability in treatment-experienced hepatitis B or C coinfected patients in DUET-1 and DUET-2. Presented at: 15th Conference on Retroviruses and Opportunistic Infections, MA, USA, 3–6 February, 2008 (Abstract 96).
   Google Scholar
• Poveda E, Garrido C, de Mendoza C et al. Prevalence of etravirine (TMC-125) resistance mutations in HIV-infected patients with prior experience of non-nucleoside reverse transcriptase inhibitors. J. Antimicrob. Chemother.60(6), 1409–1410 (2007).
   PubMed Web of Science ®Google Scholar
• Scott C, Grover D, Nelson M. Is there a role for etravirine in patients with nonnucleoside reverse transcriptase inhibitor resistance? AIDS22, 989–992 (2008).
   PubMed Web of Science ®Google Scholar